10x Genomics, Inc.

10x Genomics, Inc. is the company identified by ticker TXG on this research page. Use the overview to review the business, financial results, valuation and related news.

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Check the TXG quote and chart on the overview and Chart tabs. Confirm the quote time, currency and trading session before comparing prices; a research update time is not a quote timestamp.

The Forecast tab shows available analyst price targets for TXG. Analyst targets are separate from BTI scores and valuation estimates. Missing targets are unavailable, and forecasts do not guarantee returns.

Review 10x Genomics, Inc.'s investor-relations announcements for declared dividends, ex-dividend dates and payment dates. A missing or zero yield in a data feed alone does not establish the company's dividend policy.

Check the Earnings tab for available dates and reported results, then confirm the next announcement with 10x Genomics, Inc.'s investor-relations calendar. Estimated dates may change.

Compare TXG's Valuation and Financials tabs, including cash flow, growth assumptions and valuation multiples. BTI estimates depend on their inputs and are different from analyst price targets.

Review 10x Genomics, Inc.'s latest company filings for business-specific risks, alongside debt, profitability, competition and valuation. A BTI score summarizes research and is not a personalized investment recommendation.